Gliknik is a privately held biopharmaceutical company working to ease human suffering by creating new therapies for people living with cancer and immune disorders. Stradomers™ are the company’s first core innovative discovery; this technology was advanced under the MIPS project. MIPS Project Challenge Intravenous immunoglobulin (IVIG) is used therapeutically in dozens of autoimmune diseases and is in chronic short supply. This project was designed to identify and advance a recombinant human protein that is one of the most active fractions of IVIG, a blood product that was already known to be safe and effective but which currently comes from the pooled blood of tens of thousands of people. The most active component of this product, the Fc portion of aggregates, had been identified in publications. Gliknik invented the concept of treating autoimmune diseases with recombinant products containing multiple Fc, and selected GL-2045 as its first internally generated drug candidate, which it provided to Strome’s lab for in vitro function testing and confirmation of binding affinity to its cognate receptors. The product was later tested by Gliknik for in vivo activity in mouse models of autoimmunity. The result would be the defining of a lead pre-clinical compound to address autoimmune diseases.